Knocking back energy drinks is linked to poor quality sleep and insomnia among college students, finds a large Norwegian study published in the open access journal BMJ Open.
Acadia’s Nuplazid fails as treatment for schizophrenia in Phase 3 study
Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.